[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prurigo-nodularis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prurigo-nodularis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,38,63,87,109,141,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100592068","real-world-experience-on-using-nemolizumab-in-the-treatment-of-moderate-to--severe-prurigo-nodularis-in-adults-100592068",false,"NCT06988618","Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults","RE-UNITE PN","Inclusion Criteria:\n\n* Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN.\n* Participants greater than or equal to (\\>=) 18 years of age.\n* Participants who signed the written informed consent form (ICF).\n\nExclusion Criteria:\n\n* Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label;\n* Participants who received treatment with a drug under clinical development\u002F investigation within 3 months prior to baseline.\n* Participants who received nemolizumab previously.\n* Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and\u002For to complete the study questionnaires.","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","OBSERVATIONAL","The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.",[24],"Prurigo Nodularis","RECRUITING","2026-05-28",{"date":28,"type":29},"2026-06-01","ACTUAL",{"date":31,"type":29},"2025-08-11",{"date":33,"type":20},"2027-11-30",{"name":35,"class":36},"Galderma R&D","INDUSTRY",51,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":62},"100558698","phase-2-clinical-study-of-the-efficacy-and-safety-of-shr-1819-injection-in-adult-patients-with-prurigo-nodularis-100558698","NCT06554509","Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II\u002FIII Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis","Inclusion Criteria:\n\n1. Subjects voluntarily sign informed consent forms prior to the commencement of any proceedings related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical research protocol.\n2. The age was ≥18 at the time of signing the informed consent and gender is unlimited.\n3. Has prurigo nodularis at screening.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Screening for people with a history of heavy alcohol consumption or substance abuse in the 6 months prior to screening.\n3. Has an active skin disease or skin complications due to other diseases that may affect the evaluation of PN.\n4. PN secondary to medical conditions such as neurological or psychiatric disorders.\n5. Diagnosis of moderate to severe AD during the screening\u002Flead-in period or prior to randomization.\n6. History of clinically significant diseases (e.g., circulatory system abnormalities, endocrine system abnormalities, neurological disorders, hematologic disorders, immune system disorders, psychiatric disorders, and metabolic instability) that the researcher believes that participation in the study poses a risk to the safety of the subject or that the disease\u002Fillness worsens during the study period will affect the effectiveness or safety analysis.\n7. Phase II: Treated with biologics targeting IL-4Rα, or participated in previous clinical studies of biologics targeting IL-4Rα, including SHR-1819 injection. Phase III: Subjects who have previously received anti-IL-4Rα biologics for any indication including atopic dermatitis (AD), asthma, sinusitis, etc., and were judged by the investigator to have an inadequate response or intolerance (e.g., experienced drug-related adverse reactions requiring treatment discontinuation) must be excluded even if the washout requirement is met.\n8. Subjects with malignancy prior to screening (except for squamous cell carcinoma of the skin, basal cell carcinoma, or carcinoma in situ of the cervix that are completely resected and have no evidence of recurrence).\n9. Major surgeries are planned for the duration of the study.\n10. Other conditions that, in the opinion of the investigator, are not suitable for participation in this study.",{"count":46,"type":20},423,"INTERVENTIONAL",[49,50],"PHASE2","PHASE3","This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with Prurigo Nodularis.",[24],"2026-04-23",{"date":55,"type":29},"2026-04-29",{"date":57,"type":29},"2024-09-19",{"date":59,"type":20},"2028-10",{"name":61,"class":36},"Guangdong Hengrui Pharmaceutical Co., Ltd",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":47,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100538608","phase-3-a-study-to-investigate-the-pharmacokinetics-and-safety-of-dupilumab-in-participants-6-months-to-18-years-of-age-with-prurigo-nodularis-100538608","NCT06293053","A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to \u003C18 Years of Age With Prurigo Nodularis","A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to \u003C18 Years of Age With Prurigo Nodularis","Inclusion Criteria:\n\n* Participants must be ≥6 months to \\\u003C18 years of age, at the time of signing the informed consent.\n* A clinical diagnosis of prurigo nodularis (PN) at least 3 months prior to screening, an Investigator's global assessment for prurigo nodularis stage (IGA PN-S) score of ≥2 with presence of ≥6 pruriginous lesions at Baseline. The lesions should be present on ≥2 different body surface areas at Baseline.\n* On the worst itch numerical rating scale (WI-NRS) (for participants aged ≥6 years to \\\u003C18 years old at the screening visit) or worst-scratch\u002Fitch NRS (for participants aged ≥6 months to \\\u003C6 years at the screening visit) ranging from 0 to 10, participants must have an average worst itch score of ≥7 in the 7 days prior to Day 1.\n\nNOTE: Baseline pruritus NRS average score for maximum itch intensity will be determined based on the average of daily NRS scores for maximum intensity (the daily score ranges from 0 to 10) during the 7 days immediately preceding the Day 1\u002FBaseline visit. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score.\n\n* Participants\u002FCaregivers must be willing and able to complete a daily symptom e-Diary for the duration of the study.\n* Contraceptive use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n* Presence of active moderate to severe lesions of atopic dermatitis (AD), and\u002For other skin conditions that may interfere with the PN diagnosis including but not limited to the following: scabies, psoriasis, lymphomatoid papulosis, habitual picking, dermatitis herpetiformis, sporotrichosis, and bullous disease.\n* Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the screening visit or during the screening period.\n\nNOTE: Participants may be rescreened after infection resolves.\n\n* Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator.\n* Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study.\n* Planned or anticipated major surgical procedure during the participant's participation in this clinical trial.\n* Participants who has taken biologic therapy\u002Fsystemic immunosuppressant\u002F immunomodulator within 4 weeks before the screening visit or 5 half-lives, whichever is longer.\n* Current participation to any clinical trial of an investigational drug or device or participation within 3 months before the screening visit or 5 half-lives of the investigational compound, whichever is longer.\n* Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab.","6 Months","17 Years",{"count":73,"type":20},18,[50],"This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)\u002Fsafety study.\n\nThe study consists of 3 periods:\n\n* Screening period: 2 to 4 weeks.\n* Treatment period: 24 weeks.\n* Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods).\n\nThe total number of planned study visits for each participant will be 6.",[24],"2026-01-14",{"date":79,"type":29},"2026-01-15",{"date":81,"type":29},"2024-05-15",{"date":83,"type":20},"2027-11-03",{"name":85,"class":36},"Sanofi",14,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":97,"studyType":21,"phases":4,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100522823","a-non-interventional-study-to-describe-the-dupilumab-long-term-treatment-safety-and-patient-reported-outcomes-in-chronic-nodular-prurigo-prurigo-nodularis-in-clinical-routine-100522823","NCT06087627","A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine","Prospective, Non-interventional Observational Study to Characterize Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine","CLEAR PN","Inclusion Criteria:\n\n* Participants at least 18 years of age at baseline visit\n* Signed written informed consent\n* New initiation with dupilumab or in whom treatment with dupilumab was started within the last 7 days for moderate to severe prurigo nodularis according to the prescribing information\u002FSummary of Product Characteristics (SmPC)\n* Patients who received the initial diagnosis of PN\n\nExclusion Criteria:\n\n* Patients who have a contraindication to dupilumab according to the current prescribing information label\u002FSmPC\n* Patients who have been treated for more than 7 days with dupilumab\n* Any acute or chronic condition that, in the treating physician´s opinion, would limit the patient´s ability to complete questionnaires or to participate in this study or impact the interpretation of the results\n* Participation in an ongoing interventional or observational study that might, in the treating physician´s opinion, influence the assessments for the current study\n\nThe above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.",{"count":96,"type":20},150,"24 Months","Prurigo nodularis (PN) is a skin disease characterized by the presence of single to multiple symmetrically distributed, intensively itching nodules. The main symptom is uncontrollable itching leading to prolonged, repetitive, and uncontrollable rubbing, scratching which in turn causes injuries to the skin. In recent years, number of studies evaluating PN, the affected population and the disease burden has increased but PN remains still understudied. This non-interventional study is intended to describe the long-term effectiveness of dupilumab (Dupixent®) in participants aged 18 years or older and suffering from moderate-to-severe PN who receive dupilumab for PN treatment in a real-world setting in Germany according to the prescribing information (Summary of Product Characteristics \\[SmPC\\]). The decision to initiate dupilumab treatment is made by the treating physician and participant according to the participant's medical need and to the standard of best medical practice. This decision is made independently and before data inclusion in this non-interventional study.",[24],"2025-08-12",{"date":102,"type":29},"2025-08-13",{"date":104,"type":29},"2023-12-27",{"date":106,"type":20},"2026-12-28",{"name":85,"class":36},11,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":16,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":120,"conditions":121,"keywords":129,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":62},"100510571","determinants-of-chronic-inflammatory-skin-disease-trajectories-100510571","NCT05928169","Determinants of Chronic Inflammatory Skin Disease Trajectories","Inclusion Criteria:\n\n* dermatologist-diagnosed inflammatory skin disease\n* informed consent\n\nExclusion Criteria:\n\n* subject and\u002For the legal guardians are not able to give written informed consent\n* pregnant and breastfeeding women\n* concurrent participation in a clinical trial\n* use of systemic immunosuppressive therapy or phototherapy during the last 4 weeks or receipt of biologics therapy (e.g. dupilumab, tralokinumab) within the last 3 months\n* treatment of the target skin areas with topical corticosteroids, calcineurin inhibitors or emollients 24 hours before sample collection",true,"0 Years","80 Years",{"count":119,"type":20},1000,"Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation, clinical features and course are also largely unknown. There are currently no reliable markers that could predict or delineate patient subgroups to support patient management. The aim of this project is to identify clinical and molecular factors that correlate with disease, disease subtypes and progression through in-depth long-term clinical characterization of patients with chronic inflammatory skin diseases and examination of individual biomaterials.",[122,123,124,125,126,24,127,128],"Atopic Dermatitis","Psoriasis","Lichen Planus","Alopecia Areata","Hidradenitis Suppurativa","Cutaneous Lupus","Rosacea",[130],"Inflammatory Skin Diseases","2025-07-17",{"date":133,"type":29},"2025-07-22",{"date":135,"type":29},"2023-05-01",{"date":137,"type":20},"2032-12-31",{"name":139,"class":140},"University Hospital Schleswig-Holstein","OTHER",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":148,"targetDuration":4,"studyType":47,"phases":150,"briefSummary":151,"conditions":152,"keywords":153,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":62},"100575965","phase-3-phase-iii-clinical-study-of-mg-k10-humanized-mab-injection-in-subjects-with-prurigo-nodularis-100575965","NCT06779136","Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis","A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of a Humanized MG-K10 Mab Injection in Subjects With Prurigo Nodularis.","eligibility criteria:\n\n1. voluntarily sign the ICF and comply with all the visits and research-related procedures required by the protocol;\n2. Both men and women were required to be ≥ 18 and ≤ 80 years old at the time of signing the informed consent;\n3. the duration of PN diagnosed by a dermatologist at the time of screening was ≥ 3 months;\n4. In the range of 1-10, WI-NRS≥7 in the past 24 h at screening; WI-NRS in the week before the baseline visit The average weekly score was ≥ 7 points.\n\nExclusion criteria：\n\n1. There are skin diseases other than PN and mild atopic dermatitis (AD) that may interfere with the assessment of research outcomes.\n2. Patients who had a history of moderate to severe AD during the 6 months prior to the screening visit or screening visit.\n3. Receiving potent or super-potent TCS\u002FTCI treatment within 2 weeks before or during screening.\n\n4\\) Evidence of active tuberculosis. 5) Participation in any other clinical study within 12 weeks or 5 half-lives prior to screening",{"count":149,"type":20},160,[50],"A phase III clinical study to evaluate the efficacy and safety of a humanized MG-K10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.",[24],[154],"Prurigo nodularis","2025-04-15",{"date":157,"type":29},"2025-04-18",{"date":159,"type":29},"2025-02-26",{"date":161,"type":20},"2026-11",{"name":163,"class":36},"Shanghai Mabgeek Biotech.Co.Ltd",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":62},"100463600","china-type-ii-inflammatory-skin-disease-clinical-research-and-standardized-diagnosis-and-treatment-project-100463600","NCT05316805","China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project","China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project: a National Multicenter Prospective Cohort Study","CORNERSTONE","Inclusion Criteria:\n\n1. Patients from the medical units that has passed the data review of the National Clinical Center for Skin and Immune Diseases (see the study sites for data collection for details);\n2. patients diagnosed with type 2 inflammatory skin diseases (dermatitis\u002Feczema, urticaria, pemphigoid, prurigo nodularis).\n\nExclusion Criteria:\n\n1. patients who fail to provide informed consent form;\n2. patients who cannot complete the questionnaire independently or under the guidance of investigators",{"count":173,"type":20},100000,"In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2 inflammatory skin diseases to systematically and effectively understand the current treatment status of patients with type 2 inflammatory skin diseases, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases and help patients with type 2 inflammatory skin diseases.",[176,24],"Atopic Dermatitis Eczema","2024-08-13",{"date":179,"type":29},"2024-08-15",{"date":181,"type":29},"2021-08-31",{"date":183,"type":20},"2031-12-31",{"name":185,"class":140},"Peking University First Hospital"]